Brief: Oncoimmunology Publishes Pre-Clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor
08/03/2021 13:15
March 8 (Reuters) - Galectin Therapeutics Inc GALT.O :
* ONCOIMMUNOLOGY PUBLISHES PRE-CLINICAL RESEARCH SHOWING
GALECTIN
THERAPEUTICS’ BELAPECTIN GALECTIN-3 INHIBITOR REDUCES TUMOR
PROGRESSION IN COMBINATION WITH ANTI-OX40 THERAPY
Source text for Eikon: ID:nGNX9PFkMp
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study